We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (RACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01157065
Recruitment Status : Completed
First Posted : July 5, 2010
Results First Posted : June 4, 2013
Last Update Posted : June 4, 2013
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.

Condition or disease Intervention/treatment Phase
Exudative Age-Related Macular Degeneration Drug: AL-78898A Drug: Ranibizumab Phase 2

Detailed Description:
The study consisted of a Screening Visit (Visit 1), a Day 0 visit (Visit 2), 6 on-therapy visits at Day 1, Weeks 1, 2, 3, 4, and 8 (Visits 3-8), and an Exit Visit at Week 12 (Visit 9). Patients who met all inclusion and exclusion criteria at Visit 1 were randomized in a 3:1 ratio to receive either AL-78898A or LUCENTIS as a single 50-μL injection in the study eye. Additionally, patients received standard therapy for exudative AMD beginning at Week 2/Visit 5 if the patient was not improving per protocol-specified criteria. Beginning at Week 4/Visit 7, patients not improving received standard therapy for exudative AMD at the investigator's discretion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 99 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD
Study Start Date : June 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: AL-78898A
Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
Drug: AL-78898A
Investigational treatment

Active Comparator: Lucentis
Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
Drug: Ranibizumab
Anti-vascular endothelial growth factor (VEGF) treatment
Other Name: LUCENTIS®

Primary Outcome Measures :
  1. Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4 [ Time Frame: Week 4 ]
    The thickness of the retina was measured using a non-invasive device that produces cross-sectional and 3D images of the eye. The reduction was calculated by subtracting Week 4 visit value from the Baseline value. A positive number indicates a reduction in thickness compared to baseline, whereas a negative number indicates an increase in thickness. An increase in thickness as compared to baseline may indicate a progression of the underlying disease.

  2. Incidence of Events of Special Interest (ESI) [ Time Frame: Up to Day 30 ]
    An ESI was a protocol-specified event of scientific and medical concern specific to the Sponsor's product or program where ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. These adverse events could have been serious or nonserious and may have required further investigation in order to characterize and understand.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing to give informed consent, make the required study visits and follow instructions;
  • Newly diagnosed with exudative age-related macular degeneration (AMD);
  • Presence of primary juxta- or subfoveal choroidal neovascularization (CNV) secondary to AMD (study eye);
  • Best-corrected visual acuity (BCVA) in study eye as specified in protocol;
  • No vision-threatening ocular condition other than AMD, in the opinion of the Investigator;
  • Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

  • History or current evidence of macular or retinal disease other than exudative AMD (study eye);
  • Any evidence of fibrosis or scarring within the CNV (choroidal neovascularization)lesion (study eye);
  • Any evidence of vitreous hemorrhage (study eye);
  • History or evidence of surgery (study eye), as specified in protocol;
  • Any active systemic infection or ocular/intraocular infection or inflammation in either eye;
  • A history or current medical diagnosis of glaucoma or ocular hypertension (study eye), as specified in protocol;
  • History or current evidence of a medical condition that may in the opinion of the Investigator preclude the safe administration of test article, adherence to the scheduled study visits, safe participation in the study or affect the results of the study
  • History of severe or serious hypersensitivity to any component of the investigational product, reference product or clinically relevant sensitivity to fluorescein dye, as assessed by the Investigator;
  • Females of childbearing potential may not participate in the study if pregnant, lactating, or not using adequate birth control methods for the duration of the study;
  • Participation in any ocular or non-ocular investigational study within 30 days of screening;
  • Has received any approved or investigational therapy for AMD in the study eye with the exception of vitamins;
  • Other protocol-defined exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01157065

Layout table for location information
United States, Texas
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
Layout table for investigator information
Study Director: Mehdi Hosseini Alcon Research
Layout table for additonal information
Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT01157065    
Other Study ID Numbers: C-09-067
First Posted: July 5, 2010    Key Record Dates
Results First Posted: June 4, 2013
Last Update Posted: June 4, 2013
Last Verified: April 2013
Keywords provided by Alcon Research:
Intravitreal Injection
Macular Degeneration
VEGF treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents